The company, which has just started clinical phase III in the USA on glargine, in 2015 ranked 3d in the Chinese insulin market, with 11.2%, behind 53.1% of Nordisk and 26.7% of Sanofi, but has overtaken Eli Lilly (9%). Prices offered by Gan Li are about 20 % under those of competitors.

China Bio news release, February 7, 2018